Research on the Mechanisms of Treatment Non-response in Inflammatory Bowel Disease Based on Multi-omics Technology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In recent years, biologic agents such as infliximab, vedolizumab, and ustekinumab have demonstrated tremendous potential in the treatment of inflammatory bowel disease (IBD), altering the traditional treatment paradigm for IBD. Despite their significant efficacy, there remains a subset of patients who do not respond to biologic agents, necessitating research into the response mechanisms of biologic therapy to explore more precise treatment strategies. Preliminary work by the principal investigator has identified multiple potential responder cell subtypes to biologic agents, which may be influenced by the gut and oral microbiota. Therefore, this project proposes to investigate the mechanisms of response to biologic agents, aiming to explore more precise treatment strategies, through the integration of single-cell transcriptomics, 16S rRNA, and other multi-omics technologies on tissue samples, feces, saliva, peripheral blood, etc., from IBD patients before and after treatment. This will involve integrating bioinformatics analysis and in vitro/in vivo functional validation to elucidate the roles of treatment-responsive cell subtypes and gut and oral microbiota in the inflammatory microenvironment of the intestine, with the aim of uncovering the mechanisms of biologic agent therapy and providing new clues for the development of next-generation drug targets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods

NCT06849739

Inflammatory Bowel Diseases

NOT_YET_RECRUITING

Multi-omics to Predict Responses to Biologics in IBD

NCT05542459

Crohn Disease Ulcerative Colitis

UNKNOWN

Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Nationality in the Treatment of IBD

NCT06591013

Inflammatory Bowel Diseases

ENROLLING_BY_INVITATION NA

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

NCT06780683

Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis

RECRUITING

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

NCT06095596

Ulcerative Colitis (UC)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

primary non-response group

biologic therapy(eg:IFX,ADA,UST,VDZ)

Intervention Type DRUG

The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.

response group

biologic therapy(eg:IFX,ADA,UST,VDZ)

Intervention Type DRUG

The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biologic therapy(eg:IFX,ADA,UST,VDZ)

The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older; diagnosed with inflammatory bowel disease according to the 2019 European ECCO-ESGAR guidelines; who have not previously received any biologic therapy or, based on the treating physician's judgment, require treatment with infliximab (IFX), adalimumab (ADA), vedolizumab (VDZ), or ustekinumab (UST) after 3 months of medication.

Exclusion Criteria

* Patients who refuse treatment with infliximab, adalimumab, vedolizumab, or ustekinumab for various reasons, or those with contraindications; patients currently using antibiotics or who have been in contact with probiotics/antibiotics in the past month; those with concomitant active autoimmune diseases, active tumors, etc.; those with severe oral diseases; patients experiencing other diseases unrelated to inflammatory bowel disease during treatment but may affect the efficacy of inflammatory bowel disease treatment; pregnant or lactating women; those deemed unsuitable for participation in this study by the investigator's judgment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No